Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Inclusion Criteria: * One of the following diagnosis: * High risk aGVHD (either biopsy proven or clinical diagnosed) (see Appendix B \& C) as defined by either: * Lower gastrointestinal (GI) stage 3+ * Hyper-acute GVHD as defined by aGVHD of the GI tract within the first 14 days of transplant AND * Subjects with treatment-naive acute GVHD as defined as those who have not received previous systemic treatment for acute GVHD, except for a maximum of 7 days of no less than 1 mg/kg/day of methyl-prednisolone (or equivalent dose of prednisone). OR: * Steroid refractory aGVHD of the GI tract (either biopsy proven or clinical diagnosed) as defined by: * no response to steroid treatment (minimum daily dose: 2 mg/kg methyl-prednisolone or equivalent) lasting at least 7 days, or * progression of at least one grade within the first 72 h of treatment * ECOG Performance status \< 3 * Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source. * Patients who are able stop prophylactic antibiotics during the treatment period * Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Active malignancy * Patients with any concurrent uncontrolled clinically significant medical condition including active infection, laboratory abnormality, or psychiatric illness which could place the patient at unacceptable risk of study treatment. * Pregnant or breastfeeding women * Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data. * Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds * Patients with any severe gastrointestinal condition other than GI-GVHD. * Inability (e.g. dysphagia) to or unwilling to swallow capsules * Active gastrointestinal infection at time of enrollment * Known or suspected toxic megacolon and/or known small bowel ileus * Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy * History of total colectomy or bariatric surgery * Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy * Unable or unwilling to comply with protocol requirements * Expected life expectancy \< 6 months * Patients who have CMV \>2,000 copies/mL of whole blood or EBV \>2,000 copies/mL of whole blood.